Charles River Laboratories, William Blair

William Blair cuts Charles River Labs stock rating to Market Perform
William Blair analysts downgraded shares of Charles River Laboratories International Inc. (NYSE:CRL) stock from Outperform to Market Perform. The decision comes amid growing concerns about the company's near-term prospects,
Charles River Laboratories International (NYSE:CRL) Downgraded by William Blair to Market Perform
Charles River Laboratories International (NYSE:CRL – Get Free Report) was downgraded by equities research analysts at William Blair from an “outperform” rating to a “market perform” rating in a report released on Wednesday,
What Makes Charles River Labs (CRL) an Investment Bet?
Upslope Capital Management, an investment management firm, released its fourth-quarter 2024 investor letter. A copy of the letter can be downloaded here. Q4 was the most challenging quarter for upslope.
Charles River Labs downgraded at William Blair on less early-stage R&D spending
William Blair downgraded Charles River Laboratories to market perform citing concerns over a decline in early-stage R&D funding from large pharmas. Read more here.
Charles River downgraded to Market Perform from Outperform at William Blair
William Blair downgraded Charles River (CRL) to Market Perform from Outperform.Invest with Confidence: Follow TipRanks' Top Wall Street
Charles River Laboratories International’s (CRL) “Neutral” Rating Reiterated at UBS Group
UBS Group reaffirmed their neutral rating on shares of Charles River Laboratories International (NYSE:CRL – Free Report) in a research note released on Friday morning, MarketBeat reports. They currently have a $185.
Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors
This was the stock's second consecutive day of losses.
Hold Rating for Charles River Labs Amid Supply Chain Challenges and Mitigation Strategies
Mizuho Securities analyst Ann Hynes has maintained their neutral stance on CRL stock, giving a Hold rating yesterday.Stay Ahead of the
Barchart on MSN7h
Charles River Laboratories' Quarterly Earnings Preview: What You Need to Know
Wilmington, Massachusetts-based Charles River Laboratories International, Inc. (CRL) provides drug discovery, non-clinical ...
Charles River Labs: Near A Fundamental Trough, Growth Should Reignite Again
In Upslope’s view, CRL is a cyclical compounder going through a…cyclical downturn. Why are we bullish CRL stock? Click here ...
What Analysts Are Saying About Charles River Stock
Analysts have recently evaluated Charles River and provided 12-month price targets. The average target is $214.5, accompanied by a high estimate of $250.00 and a low estimate of $185.00. A 2.72% drop ...
Charles River CEO reveals drop in 2025 revenue outlook at JP Morgan
At the JP Morgan Healthcare Conference 2025, Charles River CEO blamed low client spending, loss of a contract and other ...
TMCnet3d
Charles River Expands Apollo™ Ecosystem, Offering Bespoke Client Experiences
Apollo for Biologics: Provides a centralized platform to submit sample submission forms, track samples, and exchange documents all in one place, ensuring accuracy and saving time.